The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy

Radiotherapy is a non-invasive standard treatment for prostate cancer (PC). However, PC develops radio-resistance, highlighting a need for agents to improve radiotherapy response. Canagliflozin, an inhibitor of sodium-glucose co-transporter-2, is approved for use in diabetes and heart failure, but i...

Descripción completa

Detalles Bibliográficos
Autores principales: Ali, Amr, Mekhaeil, Bassem, Biziotis, Olga-Demetra, Tsakiridis, Evangelia E., Ahmadi, Elham, Wu, Jianhan, Wang, Simon, Singh, Kanwaldeep, Menjolian, Gabe, Farrell, Thomas, Mesci, Aruz, Liu, Stanley, Berg, Tobias, Bramson, Jonathan L., Steinberg, Gregory R., Tsakiridis, Theodoros
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491589/
https://www.ncbi.nlm.nih.gov/pubmed/37684337
http://dx.doi.org/10.1038/s42003-023-05289-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491589/
https://www.ncbi.nlm.nih.gov/pubmed/37684337
http://dx.doi.org/10.1038/s42003-023-05289-w

Ejemplares similares